Sermorelin

Overview

Sermorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the first 29 amino acids of GHRH. It was previously FDA-approved for diagnosing and treating pediatric GH deficiency and is now widely used in anti-aging medicine.

Mechanism of Action

Sermorelin binds to GHRH receptors on pituitary somatotroph cells, stimulating the natural production and pulsatile release of growth hormone. Unlike exogenous HGH, it preserves the hypothalamic-pituitary feedback loop and does not suppress endogenous GH production.

Research Summary

Previously FDA-approved (Geref) for pediatric GH deficiency before being discontinued for commercial reasons. Clinical data supports improved body composition, sleep quality, and skin elasticity in adults. It is one of the most well-characterized GH secretagogues.

Dosing Information

Reported Side Effects

• Injection site pain or swelling
• Flushing
• Headache
• Dizziness
• Altered taste

Research References

• Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? (2005)
• Effect of low-dose growth hormone-releasing factor (GRF 1-29) on body composition and quality of life (1998)
• Growth hormone-releasing hormone: clinical studies and therapeutic aspects (1994)